Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cardiovascular disease AND gut microbiota AND insulin resistance AND obesity:

Search results

Items: 1 to 20 of 90

1.

Longevity extension in Drosophila through gut-brain communication.

Westfall S, Lomis N, Prakash S.

Sci Rep. 2018 May 30;8(1):8362. doi: 10.1038/s41598-018-25382-z.

2.

Exercising the hepatobiliary-gut axis. The impact of physical activity performance.

Molina-Molina E, Lunardi Baccetto R, Wang DQ, de Bari O, Krawczyk M, Portincasa P.

Eur J Clin Invest. 2018 Aug;48(8):e12958. doi: 10.1111/eci.12958. Epub 2018 Jun 14. Review.

PMID:
29797516
3.
4.

Microbiota and metabolic diseases.

Pascale A, Marchesi N, Marelli C, Coppola A, Luzi L, Govoni S, Giustina A, Gazzaruso C.

Endocrine. 2018 Sep;61(3):357-371. doi: 10.1007/s12020-018-1605-5. Epub 2018 May 2. Review.

PMID:
29721802
5.

Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.

Amin AM, Sheau Chin L, Teh CH, Mostafa H, Mohamed Noor DA, Abdul Kader MASK, Kah Hay Y, Ibrahim B.

Eur J Pharm Sci. 2018 May 30;117:351-361. doi: 10.1016/j.ejps.2018.03.011. Epub 2018 Mar 8.

PMID:
29526765
6.

Insulin resistance in obesity: an overview of fundamental alterations.

Barazzoni R, Gortan Cappellari G, Ragni M, Nisoli E.

Eat Weight Disord. 2018 Apr;23(2):149-157. doi: 10.1007/s40519-018-0481-6. Epub 2018 Feb 3. Review.

PMID:
29397563
7.

Diabetes and branched-chain amino acids: What is the link?

Bloomgarden Z.

J Diabetes. 2018 May;10(5):350-352. doi: 10.1111/1753-0407.12645. Epub 2018 Feb 13.

PMID:
29369529
8.

Mechanistically different effects of fat and sugar on insulin resistance, hypertension, and gut microbiota in rats.

Ramos-Romero S, Hereu M, Atienza L, Casas J, Jáuregui O, Amézqueta S, Dasilva G, Medina I, Nogués MR, Romeu M, Torres JL.

Am J Physiol Endocrinol Metab. 2018 Jun 1;314(6):E552-E563. doi: 10.1152/ajpendo.00323.2017. Epub 2018 Jan 2.

PMID:
29351480
9.

Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions.

Solas M, Milagro FI, Ramírez MJ, Martínez JA.

Curr Opin Pharmacol. 2017 Dec;37:87-92. doi: 10.1016/j.coph.2017.10.005. Epub 2017 Nov 5. Review.

PMID:
29107872
10.

The Microbiome That Shapes Us: Can It Cause Obesity?

Omer E, Atassi H.

Curr Gastroenterol Rep. 2017 Oct 27;19(12):59. doi: 10.1007/s11894-017-0600-y. Review.

PMID:
29080046
11.

Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.

Nguyen TTB, Jin YY, Chung HJ, Hong ST.

Molecules. 2017 Oct 24;22(10). pii: E1795. doi: 10.3390/molecules22101795. Review.

12.

Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome.

de Toro-Martín J, Arsenault BJ, Després JP, Vohl MC.

Nutrients. 2017 Aug 22;9(8). pii: E913. doi: 10.3390/nu9080913. Review.

13.

DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis.

Xu P, Hong F, Wang J, Wang J, Zhao X, Wang S, Xue T, Xu J, Zheng X, Zhai Y.

Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2690-2701. doi: 10.1016/j.bbagen.2017.07.013. Epub 2017 Jul 20.

PMID:
28736228
14.

Innate immunity orchestrates adipose tissue homeostasis.

Lin YW, Wei LN.

Horm Mol Biol Clin Investig. 2017 Jun 23;31(1). pii: /j/hmbci.2017.31.issue-1/hmbci-2017-0013/hmbci-2017-0013.xml. doi: 10.1515/hmbci-2017-0013. Review.

PMID:
28672736
15.

Food additives, contaminants and other minor components: effects on human gut microbiota-a review.

Roca-Saavedra P, Mendez-Vilabrille V, Miranda JM, Nebot C, Cardelle-Cobas A, Franco CM, Cepeda A.

J Physiol Biochem. 2018 Feb;74(1):69-83. doi: 10.1007/s13105-017-0564-2. Epub 2017 May 9. Review.

PMID:
28488210
16.

[Microbiota and metabolic syndrome].

Altuntaş Y, Batman A.

Turk Kardiyol Dern Ars. 2017 Apr;45(3):286-296. doi: 10.5543/tkda.2016.72461. Turkish.

17.
18.

Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders.

Peyrol J, Riva C, Amiot MJ.

Nutrients. 2017 Mar 20;9(3). pii: E306. doi: 10.3390/nu9030306. Review.

19.

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.

Targher G, Byrne CD.

Nat Rev Nephrol. 2017 May;13(5):297-310. doi: 10.1038/nrneph.2017.16. Epub 2017 Feb 20. Review.

PMID:
28218263
20.

Dietary and commercialized fructose: Sweet or sour?

Yerlikaya A, Dagel T, King C, Kuwabara M, Lanaspa MA, Andres-Hernando A, Covic A, Manitius J, Sag AA, Kanbay M.

Int Urol Nephrol. 2017 Sep;49(9):1611-1620. doi: 10.1007/s11255-017-1544-8. Epub 2017 Feb 16. Review. Erratum in: Int Urol Nephrol. 2017 Apr 5;:.

PMID:
28210913

Supplemental Content

Loading ...
Support Center